Ph.D., Principal Investigator
Laboratory of Tumor Progression and Metastasis
Research Interests or Current Research Focus
The long term goal of my research will be aimed at elucidating the underlying mechanisms of how epigenetic regulations impact tumors progression and metastasis, with a prime focus on prostate cancer and colorectal cancer. To achieve these goals, we will employ multidisciplinary approaches including genetically engineered mouse models (GEM), modern molecular biology, computational biology and patient sample analysis. We believe the knowledge acquired in our studies will lead to the development of alternative therapeutic approaches for cancer prevention and intervention. The lab is currently conducting the researches in the following aspects:
(1) Epigenetic regulation in prostate tumorigenesis and castration resistance
(2) Epigenetic regulation in colorectal cancer, with a prime focus on the role of cancer stem cells transformation
(3) Epigenetic regulation in tumor microenvironment
Major Research Achievement
First, we have identified that COUP-TFII, a member of the nuclear receptor family, serves as one of the major angiogenic regulators within tumor microenvironment to promote tumor progression. Second, we have uncovered a cell-autonomous role of COUP-TFII in inhibiting TGF-beta-dependent growth barrier to drive full malignant progression of prostate cancer, suggesting that COUP-TFII might be a potential drug target for cancer intervention. Third, we discover a nuclear receptor coactivator, SRC-2 is critical for prostate cancer metastasis and castration resistance through regulation of PI3K/AKT and MAPK signaling.
1996-2000: Sichuan University, Bachelor
2000-2005: Institute of Biochemistry and Cell Biology, Shanghai Institute of Life Science, Chinese Academy of Science, Ph.D.
Major Academic Appointments
2005-2010: Postdoctoral Associate, Baylor College of Medicine
2010-2012: Instructor, Baylor College of Medicine
2012-2014: Assistant Professor, Baylor College of Medicine
2014-Present: Principle Investigator, Institute of Health Sciences, SIBS, CAS / SJTUSM
Honors, Certificates, and Academic Society
2014: Recipient of the Recruitment Program of Global Experts (Young Program)
2010: Travel award of Keystone nuclear receptor symposium
- Yuan H#, Li N#, Fu D#, Ren J, Hui J, Peng J, Liu Y, Qiu T, Jiang M, Pan Q, Han Y, Wang X, Li Q and Qin J*. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. Journal of Clinical Investigation, 2017 Aug 21 [Epub ahead of print] （*通讯作者）
- Li Y#, Peng J#, Sun T#, Li N, Zhang L, Ren J, Yuan H, Kan S, Pan Q, Li X, Ding Y, Jiang M, Cong X, Tan M, Ma Y, Fu D, Cai S, Xiaog Y, Wang X and Qin J*. Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNF-mediated inflammation and apoptosis. Proc Natl Acad Sci U S A. 114(19):E3796-E3805 （*通讯作者）
- Li N#, Xue W#, Yuan H#, Dong B, Ding Y, Liu Y, Jiang M, Kan S, Sun T, Ren J, Pan Q, Li X, Zhang P, Hu G, Wang Y, Wang X, Li Q, Qin J*. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. Journal of Clinical Investigation, 2017; 127(4):1284-1302.（*通讯作者）
- Qin J*,#, Lee HJ#, Wu SP, Lin SC, Lanz Rb, Creighton CJ, DeMayo FJ, Tsai SY*, Tsai MJ*. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. Journal of Clinical Investigation, 2014; 124(11):5013-26 (*共同通讯作者)
- Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng C-M, Frolov A, Ayala G, Lin X, Feng X-H, Ittmann M, Tsai S-J, Tsai MJ* and Tsai SY*. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate Tumorigenesis. Nature. 2013 493, 236-240.